Spectrum Pharmaceuticals Inc. (SPPI)

8.95
NASDAQ : Health Technology
Prev Close 9.45
Day Low/High 8.83 / 9.55
52 Wk Low/High 6.22 / 21.80
Avg Volume 752.60K
Exchange NASDAQ
Shares Outstanding 104.06M
Market Cap 983.32M
EPS -1.20
P/E Ratio N/A
Div & Yield N.A. (N.A)
The 10 Most Heavily Shorted Bio-Pharma Stocks

The 10 Most Heavily Shorted Bio-Pharma Stocks

The No. 1 stock on this list has more than half its float short.

Biotech Stock 'Hate' Mailbag: Readers Riot Over Galena, Prana

Biotech Stock 'Hate' Mailbag: Readers Riot Over Galena, Prana

I've received so much hate email and tweets over the past week, enough to fill a special edition of the Mailbag.

Spectrum Pharmaceuticals Announces FDA’s Acceptance Of NDA Filing For Beleodaq™ (belinostat) For Injection, A Novel Pan-HDAC Inhibitor

Spectrum Pharmaceuticals Announces FDA’s Acceptance Of NDA Filing For Beleodaq™ (belinostat) For Injection, A Novel Pan-HDAC Inhibitor

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations and a primary focus in Hematology and Oncology, announced today that its New Drug...

SPPI Makes Notable Cross Below Critical Moving Average

SPPI Makes Notable Cross Below Critical Moving Average

In trading on Friday, shares of Spectrum Pharmaceuticals Inc crossed below their 200 day moving average of $8.38, changing hands as low as $8.33 per share. Spectrum Pharmaceuticals Inc shares are currently trading off about 2.4% on the day.

Spectrum Pharmaceuticals To Present At The J.P. Morgan Healthcare Conference In San Francisco On January 16th

Spectrum Pharmaceuticals To Present At The J.P. Morgan Healthcare Conference In San Francisco On January 16th

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that an overview of...

SPPI Crosses Below Key Moving Average Level

SPPI Crosses Below Key Moving Average Level

In trading on Tuesday, shares of Spectrum Pharmaceuticals Inc crossed below their 200 day moving average of $8.22, changing hands as low as $8.20 per share. Spectrum Pharmaceuticals Inc shares are currently trading up about 1.2% on the day.

Making a Plan for Spectrum

Making a Plan for Spectrum

You can add to long with close above $8.57.

Spectrum Pharmaceuticals Announces Pricing Of $100 Million Convertible Notes Offering

Spectrum Pharmaceuticals Announces Pricing Of $100 Million Convertible Notes Offering

Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI) announced today the pricing of its offering of $100 million aggregate principal amount of 2.

Commit To Buy Spectrum Pharmaceuticals At $4.85, Earn 8.2% Using Options

Commit To Buy Spectrum Pharmaceuticals At $4.85, Earn 8.2% Using Options

Investors considering a purchase of Spectrum Pharmaceuticals shares, but tentative about paying the going market price of $8.33/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2015 put at the $4.85 strike, which has a bid at the time of this writing of 40 cents.

Spectrum Pharmaceuticals Announces Offering Of $100 Million Of Convertible Notes

Spectrum Pharmaceuticals Announces Offering Of $100 Million Of Convertible Notes

Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI) announced today that it intends, subject to market and other conditions, to offer $100 million aggregate principal amount of convertible senior notes due 2018 (the ...

Spectrum Pharmaceuticals Highlights Encouraging FOLOTYN® And MARQIBO® Clinical Data Presented At The 55th Annual Meeting Of The American Society Of Hematology (ASH)

Spectrum Pharmaceuticals Highlights Encouraging FOLOTYN® And MARQIBO® Clinical Data Presented At The 55th Annual Meeting Of The American Society Of Hematology (ASH)

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced encouraging clinical...

Spectrum Pharmaceuticals Announces Submission Of New Drug Application For Belinostat, A Novel Pan-HDAC Inhibitor

Spectrum Pharmaceuticals Announces Submission Of New Drug Application For Belinostat, A Novel Pan-HDAC Inhibitor

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations and a primary focus in hematology and oncology, announced today the that the company...

Spectrum Pharmaceuticals Highlights 13 Abstracts At The 55th Annual Meeting Of The American Society Of Hematology (ASH), New Orleans, Louisiana, December 7-10, 2013

Spectrum Pharmaceuticals Highlights 13 Abstracts At The 55th Annual Meeting Of The American Society Of Hematology (ASH), New Orleans, Louisiana, December 7-10, 2013

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced key presentations of...

Spectrum Pharmaceuticals Stock Sees Short Interest Drop 11%

Spectrum Pharmaceuticals Stock Sees Short Interest Drop 11%

The most recent short interest data has been released by the NASDAQ for the 11/15/2013 settlement date, which shows a 1,861,784 share decrease in total short interest for Spectrum Pharmaceuticals Inc , to 15,136,925, a decrease of 10.95% since 10/31/2013. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Spectrum Pharmaceuticals Reports Financial Results For Third Quarter 2013

Spectrum Pharmaceuticals Reports Financial Results For Third Quarter 2013

Spectrum Pharmaceuticals (Nasdaq: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, announced today financial results for...

Spectrum Pharmaceuticals To Present Corporate Update At The Credit Suisse 2013 Healthcare Conference In Arizona On November 13th

Spectrum Pharmaceuticals To Present Corporate Update At The Credit Suisse 2013 Healthcare Conference In Arizona On November 13th

Spectrum Pharmaceuticals (Nasdaq: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that an overview of the...

Spectrum Pharmaceuticals Announces Third Quarter 2013 Financial Results Teleconference And Webcast

Spectrum Pharmaceuticals Announces Third Quarter 2013 Financial Results Teleconference And Webcast

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced it will host a ...

Spectrum Pharmaceuticals Announces Completion Of Enrollment, In Pivotal Trial Of Captisol-Enabled® (Propylene Glycol-Free) Melphalan

Spectrum Pharmaceuticals Announces Completion Of Enrollment, In Pivotal Trial Of Captisol-Enabled® (Propylene Glycol-Free) Melphalan

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations and a primary focus in hematology and oncology, announced today the completion of...

SPPI Crosses Above Key Moving Average Level

SPPI Crosses Above Key Moving Average Level

In trading on Tuesday, shares of Spectrum Pharmaceuticals Inc crossed above their 200 day moving average of $8.72, changing hands as high as $8.76 per share. Spectrum Pharmaceuticals Inc shares are currently trading up about 0.9% on the day.

4 Biotech Stocks Under $10 to Watch

4 Biotech Stocks Under $10 to Watch

Keep these under-$10 biotech stocks on your radar.

Spectrum Pharmaceuticals Is Now Oversold (SPPI)

Spectrum Pharmaceuticals Is Now Oversold (SPPI)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Spectrum Pharmaceuticals To Present Corporate Update At The Morgan Stanley Global Healthcare Conference In New York City On September 11th

Spectrum Pharmaceuticals To Present Corporate Update At The Morgan Stanley Global Healthcare Conference In New York City On September 11th

Spectrum Pharmaceuticals (NasdaqGS:SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that an overview of...

Spectrum Pharmaceuticals Launches Marqibo® (vinCRIStine Sulfate LIPOSOME Injection) And Ships First Commercial Orders

Spectrum Pharmaceuticals Launches Marqibo® (vinCRIStine Sulfate LIPOSOME Injection) And Ships First Commercial Orders

Spectrum Pharmaceuticals (NasdaqGS:SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, announced today the launch of Marqibo.

Commit To Purchase Spectrum Pharmaceuticals At $4.85, Earn 12.4%

Commit To Purchase Spectrum Pharmaceuticals At $4.85, Earn 12.4%

Investors considering a purchase of Spectrum Pharmaceuticals Inc shares, but tentative about paying the going market price of $7.69/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2015 put at the $4.85 strike, which has a bid at the time of this writing of 60 cents.

Spectrum Pharmaceuticals Reports Financial Results For Second Quarter 2013

Spectrum Pharmaceuticals Reports Financial Results For Second Quarter 2013

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, announced today financial results for...

5 Stocks Poised to Pop on Bullish Earnings

5 Stocks Poised to Pop on Bullish Earnings

These heavily shorted stocks could get squeezed much higher if they report positive earnings.

Spectrum Pharmaceuticals Announces Second Quarter 2013 Financial Results Teleconference And Webcast

Spectrum Pharmaceuticals Announces Second Quarter 2013 Financial Results Teleconference And Webcast

Spectrum Pharmaceuticals (NasdaqGS:SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced it will host a ...

Spectrum Can Generate Profits From Misfit Cancer Drugs

Spectrum Can Generate Profits From Misfit Cancer Drugs

Even modest-selling drugs can be profitable when sold by a single, low-cost salesforce.

The Deal: Spectrum Expands Cancer Line With Talon Buy

The Deal: Spectrum Expands Cancer Line With Talon Buy

Las Vegas-based Spectrum Pharmaceuticals is amping up its cancer therapy offerings with the acquisition of private equity-backed Talon Therapeutics.

Spectrum Pharmaceuticals Acquires Talon Therapeutics, Inc.

Spectrum Pharmaceuticals Acquires Talon Therapeutics, Inc.

Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company with fully-integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that, through a...

TheStreet Quant Rating: D (Sell)